LGX 818
Modify Date: 2024-01-02 19:53:14
LGX 818 structure
|
Common Name | LGX 818 | ||
|---|---|---|---|---|
| CAS Number | 1269440-17-6 | Molecular Weight | 540.011 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H27ClFN7O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LGX 818Encorafenib (LGX818) is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM). |
| Name | methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate |
|---|---|
| Synonym | More Synonyms |
| Description | Encorafenib (LGX818) is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM). |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.3 nM (BRafV600E) |
| In Vitro | Encorafenib (LGX818) is a potent drug that can prevents diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf[1]. Encorafenib (LGX818) (10 nM) suppresses the ERK/MAPK pathway and displays marked inhibition of pERK in A375, G361 and SK-MEL-24 cells. 10 nM Encorafenib (LGX818) treatment for 12 days potently inhibits colony formation in A375, G361 and SK-MEL-24 cells, but not in RPMI7951 and C8161 cells. Encorafenib (LGX818) treatment induces a steady increase in the β-catenin level in G361 cells over time[2]. |
| References |
[1]. Compounds and compositions as protein kinase inhibitors. Patent WO 2011025927 A1 |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H27ClFN7O4S |
| Molecular Weight | 540.011 |
| Exact Mass | 539.151794 |
| PSA | 152.00000 |
| LogP | 2.56 |
| Index of Refraction | 1.641 |
| Storage condition | -20℃ |
| Water Solubility | Insuluble (7.0E-4 g/L) (25 ºC) |
| LGX-818 |
| Encorafenib |
| NVP-LGX818-NXA |
| LGX818 |
| Encorafenib (LGX818) |
| methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate |
| T6N CNJ BM1Y1&MVO1& D- DT5NNJ AY1&1 CR CG FF EMSW1 &&S Form |
| UNII-8L7891MRB6 |
| Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester |
| (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate |